Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment

Torun, Ege Sinan; Daglar Aday, Aynur; Nalcaci, Meliha

doi:10.3906/sag-2101-81

Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment

Ege Sinan TORUN, (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, İstanbul, Türkiye)

Aynur DAĞLAR ADAY, (İstanbul Üniversitesi, Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, İç Hastalıkları Anabilim Dalı, İstanbul, Türkiye)

Meliha NALÇACI (İstanbul Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, İç Hastalıkları Anabilim Dalı, İstanbul, Türkiye)

Turkish Journal of Medical Sciences

2 0

Yıl: 2021 Cilt: 51 Sayı: 5 Sayfa Aralığı: 2451 - 2460 Metin Dili: İngilizce DOI: 10.3906/sag-2101-81 İndeks Tarihi: 07-01-2022

Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment

Öz:

Background/aim: Activation-induced cytidine deaminase (AID) enables antibody diversity in B lymphocytes. It may also have an effect on MDS pathogenesis by causing somatic mutations and by inducing epigenetic changes in myeloid cells. This study aimed to compare AID expression of MDS patients with healthy controls, of MDS patients in different risk groups, and of MDS patients according to their treatment. Materials and methods: Total RNA was isolated and complementary DNA (cDNA) was transcribed from the peripheral blood samples of MDS patients and healthy controls. AID and the reference gene HPRT1 were analyzed using quantitative real-time PCR (QRT-PCR). AID expression relative to HPRT1 was calculated. Patients were classified into “lower risk” and “higher risk” subgroups according to their initial IPSS and IPSS-R scores and their MDS subtypes at the time of study. Patients were also divided into two groups based on receiving treatment with hypomethylating agents. AID expressions of different groups were compared using the Mann–Whitney U test. Results: Thirty MDS patients and thirty healthy controls were included. AID expression in MDS patients was significantly higher compared to healthy controls (p < 0.001). There was no significant difference in AID expression of “lower risk” and “higher risk” subgroups of patients. Patients that received hypomethylating agents did not have a significant difference in AID expression compared with patients that did not receive hypomethylating agents. Conclusion: AID expression is increased in the peripheral blood of MDS patients compared to healthy controls. However, AID expression is not significantly different in “lower risk” and “higher risk” subgroups and in patients treated with hypomethylating agents. Increased AID expression may be an early step in MDS pathogenesis.Key words: Activation induced cytidine deaminase, hypomethylating agents, myelodysplastic syndrome

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Wang ES, Berliner N. Hematopoiesis and hematopoietic failure. In: Andreoli TE, Benjamin IJ, Griggs RC, Wing EJ (editors). Andreoli and Carpenter's Cecil Essentials of Medicine. 8th ed. Philadelphia, PA, USA: Saunders/Elsevier; 2010. pp. 503-506.
2. Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. American Journal of Hematology 2015; 90: 831-841. doi: 10.1002/ajh.24102
3. Itzykson R, Fenaux P. Epigenetics of myelodysplastic syndromes. Leukemia 2014; 28: 497-506. doi: 10.1038/leu.2013.343
4. Visconte V, Tiu RV, Rogers HJ. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood research 2014; 49 (4): 216-227. doi: 10.5045/br.2014.49.4.216
5. Thol F, Winschel C, Lüdeking A, Yun H, Friesen I et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 2011; 96: 1870-1873. doi: 10.3324/haematol.2011.045559
6. Challen GA, Sun D, Jeong M, Luo M, Jelinek J et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics 2011; 44: 23-31. doi: 10.1038/ng.1009
7. Walter MJ, Ding L, Shen D, Shao J, Grilot M et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25: 1153-1158. doi: 10.1038/leu.2011.44
8. Ko M, An J, Bandukwala HS, Chavez L, Aijö T et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 2013; 497: 122-126. doi: 10.1038/nature12052
9. Ponnaluri VK, Maciejewski JP, Mukherji M. A mechanistic overview of TET-mediated 5-methylcytosine oxidation. Biochemical and Biophysical Research Communications 2013; 436: 115-120. doi:
10.1016/j.bbrc.2013.05.077 10. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009; 113: 6403-6410. doi: 10.1182/blood-2009-02-205690
11. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genetics 2009; 41: 838- 842. doi: 10.1038/ng.391
12. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116: 3923-3932. doi: 10.1182/blood-2010- 03-274704
13. Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute leukemia patients. Leukemia 2014; 28: 1586-1595. doi: 10.1038/leu.2014.55
14. Delker RK, Fugmann SD, Papavasiliou FN. A coming-of-age story: activation-induced cytidine deaminase turns 10. Nature Immunology 2009; 10 (11): 1147-1153. doi: 10.1038/ni.1799
15. Durandy, A. Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation. European Journal of Immunology 2003; 33: 2069-2073.
16. Chua KF, Alt FW, Manis JP. The function of AID in somatic mutation and class switch recombination: upstream or downstream of DNA breaks. Journal of Experimental Medicine 2002; 195: 37-41. doi: 10.1084/jem.20020380
17. Kinoshita K, Nonaka T. The dark side of activation-induced cytidine deaminase: relationship with leukemia and beyond. International Journal of Hematology 2006; 83 (3): 201-207.
18. Rai K, Huggins IJ, James SR, Karpf AR, Jones D et al. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 2008; 135 (7): 1201-1212. doi: 10.1016/j.cell.2008.11.042
19. Popp C, Dean W, Feng S, Cokus SJ, Andrews S et al. Genomewide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency. Nature 2010; 463 (7284): 1101-1105. doi: 10.1038/nature08829
20. Kumar R, DiMenna L, Schrode N, Liu TC, Franck P et al. AID stabilizes stem-cell phenotype by removing epigenetic memory of pluripotency genes. Nature 2013; 500 (7460): 89- 92. doi: 10.1038/nature12299
21. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114 (5): 937- 951. doi: 10.1182/blood-2009-03-209262
22. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P et al. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood 1997; 89 (6): 2079-2088.
23. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120 (12): 2454- 2465.
24. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols 2008; 3 (6): 1101- 1108.
25. Marusawa H. Aberrant AID expression and human cancer development. International Journal of Biochemistry & Cell Biology 2008; 40 (8): 1399-1402. doi: 10.1016/j.biocel.2008.01.018
26. Goto A, Hirahashi M, Osada M, Nakamura K, Yao T et al. Aberrant activation-induced cytidine deaminase expression is associated with mucosal intestinalization in the early stage of gastric cancer. Virchows Archiv 2011; 458 (6): 717-724. doi: 10.1007/s00428-011-1086-x
27. Ramiro AR, Jankovic M, Callen E, Diflippantonio S, Chen HT et al. Role of genomic instability and p53 in AID-induced c-mycIgh translocations. Nature 2006; 440 (7080): 105-109.
28. Takizawa M, Tolarova H, Li Z, Dubois W, Lim S et al. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. Journal of Experimental Medicine 2008; 205 (9): 1949-1957. doi: 10.1084/jem.20081007
29. Lossos IS, Levy R, Alizadeh AA. AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity. Leukemia 2004; 18 (11): 1775-1779.
30. Feldhahn N, Henke N, Melchior K, Duy C, Soh BN et al. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. Journal of Experimental Medicine 2007; 204 (5): 1157-1166.
31. Hançer VS, Köse M, Diz-Küçükkaya R, Yavuz AS, Aktan M. Activation-induced cytidine deaminase mRNA levels in chronic lymphocytic leukemia. Leukemia & Lymphoma 2011; 52: 79- 84. doi: 10.3109/10428194.2010.531410
32. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009; 16 (3): 232-245. doi: 10.1016/j.ccr.2009.07.030
33. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011; 118 (14): 3932- 3941. doi: 10.1182/blood-2010-10-311019
34. Fried I, Bodner C, Pichler MM, Lind K, Beham-Schmid C et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica 2012; 97: 246-250. doi: 10.3324/haematol.2011.051581
35. Arioka Y, Watanabe A, Saito K, Yamada Y. Activation-induced cytidine deaminase alters the subcellular localization of tet family proteins. Plos One 2012; 7 (9), e45031. doi: 10.1371/journal.pone.0045031
36. Tsai CT, Yang PM, Chern TR, Chuang SH, Lin JH et al. AID downregulation is a novel function of the DNMT inhibitor 5- aza-deoxycytidine. Oncotarget 2014; 5 (1): 211-223.
37. Langer F, Dingemann J, Kreipe H, Lehmann U. Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leukemia Research 2005; 29 (3): 325-329. doi: 10.1016/j.leukres.2004.08.004
38. Pleyer L, Greil R. Digging deep into “dirty” drugs – modulation of the methylation machinery. Drug Metabolism Reviews 2015; 47 (2): 252-279. doi: 10.3109/03602532.2014.995379
39. Morgan HD, Dean W, Coker HA, Reik W, Petersen-Mahrt SK. Activation-induced cytidine deaminase deaminates 5- Methylcytosine in DNA and is expressed in pluripotent tissues implications for epigenetic reprogramming. Journal of Biological Chemistry 2004; 279 (50): 52353-52360.
40. Bochtler M, Kolano A, Xu GL. DNA demethylation pathyways: Additional players and regulators. BioEssays 2017; 39 (1): 1- 13. doi: 10.1002/bies.201600178

APA	Torun E, Daglar Aday A, Nalcaci M (2021). Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment. , 2451 - 2460. 10.3906/sag-2101-81
Chicago	Torun Ege Sinan,Daglar Aday Aynur,Nalcaci Meliha Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment. (2021): 2451 - 2460. 10.3906/sag-2101-81
MLA	Torun Ege Sinan,Daglar Aday Aynur,Nalcaci Meliha Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment. , 2021, ss.2451 - 2460. 10.3906/sag-2101-81
AMA	Torun E,Daglar Aday A,Nalcaci M Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment. . 2021; 2451 - 2460. 10.3906/sag-2101-81
Vancouver	Torun E,Daglar Aday A,Nalcaci M Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment. . 2021; 2451 - 2460. 10.3906/sag-2101-81
IEEE	Torun E,Daglar Aday A,Nalcaci M "Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment." , ss.2451 - 2460, 2021. 10.3906/sag-2101-81
ISNAD	Torun, Ege Sinan vd. "Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment". (2021), 2451-2460. https://doi.org/10.3906/sag-2101-81

APA	Torun E, Daglar Aday A, Nalcaci M (2021). Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment. Turkish Journal of Medical Sciences, 51(5), 2451 - 2460. 10.3906/sag-2101-81
Chicago	Torun Ege Sinan,Daglar Aday Aynur,Nalcaci Meliha Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment. Turkish Journal of Medical Sciences 51, no.5 (2021): 2451 - 2460. 10.3906/sag-2101-81
MLA	Torun Ege Sinan,Daglar Aday Aynur,Nalcaci Meliha Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment. Turkish Journal of Medical Sciences, vol.51, no.5, 2021, ss.2451 - 2460. 10.3906/sag-2101-81
AMA	Torun E,Daglar Aday A,Nalcaci M Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment. Turkish Journal of Medical Sciences. 2021; 51(5): 2451 - 2460. 10.3906/sag-2101-81
Vancouver	Torun E,Daglar Aday A,Nalcaci M Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment. Turkish Journal of Medical Sciences. 2021; 51(5): 2451 - 2460. 10.3906/sag-2101-81
IEEE	Torun E,Daglar Aday A,Nalcaci M "Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment." Turkish Journal of Medical Sciences, 51, ss.2451 - 2460, 2021. 10.3906/sag-2101-81
ISNAD	Torun, Ege Sinan vd. "Activation-induced cytidine deaminase expression in patients with myelodysplastic syndrome and its relationship with prognosis and treatment". Turkish Journal of Medical Sciences 51/5 (2021), 2451-2460. https://doi.org/10.3906/sag-2101-81